Last reviewed · How we verify
JTX-8064
At a glance
| Generic name | JTX-8064 |
|---|---|
| Also known as | Anti-LILRB2, Anti-ILT4 |
| Sponsor | Jounce Therapeutics, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study of JTX-8064, as Monotherapy and in Combination With a PD-1 Inhibitor, in Adult Subjects With Advanced Refractory Solid Tumors (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- JTX-8064 CI brief — competitive landscape report
- JTX-8064 updates RSS · CI watch RSS
- Jounce Therapeutics, Inc. portfolio CI